Browsing by Yonsei Author : Lim, Sun Min

eperson profile image
Name:
Lim, Sun Min [임선민]
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 86

This table browses all dspace content
Issue DateTitleJournal Title
2023Management of HER2 alterations in non-small cell lung cancer - The past, present, and futureLUNG CANCER
2023Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial NATURE COMMUNICATIONS
2023A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study) CANCERS
2023Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies CANCERS
2023Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy TRANSLATIONAL LUNG CANCER RESEARCH
2023Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea Cancer Treatment and Research Communications
2023Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter studyLUNG CANCER
2023Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing CANCER RESEARCH AND TREATMENT
2023Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCCLINICAL CANCER RESEARCH
2023Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)CLINICAL LUNG CANCER
2022YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment FRONTIERS IN CHEMISTRY
2022Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experienceCANCER IMMUNOLOGY IMMUNOTHERAPY
2022Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity FRONTIERS IN ONCOLOGY
2022Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice CURRENT ONCOLOGY
2022The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges FRONTIERS IN ONCOLOGY
2022SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models CLINICAL & TRANSLATIONAL IMMUNOLOGY
2022Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor YONSEI MEDICAL JOURNAL
2022Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung CancerCANCER RESEARCH
2022Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLCCANCER DISCOVERY
2022Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group CANCER RESEARCH AND TREATMENT
2022Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2021Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patientsJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2021The promise of bispecific antibodies: Clinical applications and challengesCANCER TREATMENT REVIEWS
2021Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma CLINICAL CANCER RESEARCH
2021Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2021A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma CANCER MEDICINE
2021Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study CANCERS
2021Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib JTO Clinical and Research Reports
2021Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors CANCERS
2021Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLCJOURNAL OF THORACIC ONCOLOGY
2021Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer PHARMACEUTICALS
2021Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?JOURNAL OF THORACIC ONCOLOGY
2021Genomic landscape of extraordinary responses in metastatic breast cancer COMMUNICATIONS BIOLOGY
2021Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma FRONTIERS IN IMMUNOLOGY
2020The Next Target for NSCLC: Let It Be "RET"JOURNAL OF THORACIC ONCOLOGY
2020Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea CANCER RESEARCH AND TREATMENT
2020AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activationLUNG CANCER
2020Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLCCANCER DISCOVERY
2020Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer JOURNAL FOR IMMUNOTHERAPY OF CANCER
2020Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma CANCERS
2020Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer BMC CANCER
2020Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives IMMUNE NETWORK
2017Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.JOURNAL OF CLINICAL ONCOLOGY
2017Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung CancerJOURNAL OF THORACIC ONCOLOGY
2017Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma CANCER RESEARCH AND TREATMENT
2016Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus ONCOTARGET
12

Browse

Links